Sep 7, 2023 8:01am EDT Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
Sep 5, 2023 8:01am EDT Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14 – Dec 31, 2023 Second Quarter 2023 Financial Results Conference Call Earnings Release PDF HTML Audio Earnings Webcast 10-Q Filing PDF HTML 10-Q/A Filing PDF HTML XBRL ZIP XLS